They’re Back… The Specter of FDA’s De-Facto Rx Ad Ban

Session details:

Imagine if you will… an HHS Secretary hell-bent on banning pharmaceutical TV advertising and digital marketing in the United States – frustrated over the last two years by 1) a White House that pulled back a draft executive order, 2) having to publicly confess to Senators that advertising is commercial speech protected by the First Amendment, 3) a chilling FDA enforcement action that unintentionally created a 53% increase in Rx ads over the next six months, and 4) lack of support by FDA leadership to push a “loophole” de-facto Rx ad ban.

Now, you wake up during a thunderstorm to a toy phone ringing…

The entire Senate-confirmed FDA leadership has been removed, and there’s an announcement of a new federal rulemaking to “eliminate the option for prescription drug advertisements broadcast” by removing the "adequate provision" clause in FDA regulations and industry guidance by the end of this year.

Is this scary and real threat… Yes. You’d be right to think you are living out a scene from Poltergeist V or the Twilight Zone Redux.

Should you dare to attend this session, attendees will gain insights into:

• How the Secretary wants you to act (and why you shouldn’t take the bait)
• The strong legal foundation of Rx advertising as commercial speech
• Over 60 years of legislative and FDA regulatory history
• Real-world outcome data countering MAHA claims, and
• Enough heads-up to act with intention, legally challenging any such rulemaking